{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:00:21Z","timestamp":1768010421556,"version":"3.49.0"},"reference-count":198,"publisher":"Elsevier BV","issue":"13-14","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":288,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"National Institutes of Health","award":["DK-96392"],"award-info":[{"award-number":["DK-96392"]}]},{"name":"National Institutes of Health","award":["P01 HL96974"],"award-info":[{"award-number":["P01 HL96974"]}]},{"name":"National Institutes of Health","award":["CA-143971"],"award-info":[{"award-number":["CA-143971"]}]},{"name":"FP7 \u2014 The European Union Seventh Framework Programme 2007\u20132011","award":["242209"],"award-info":[{"award-number":["242209"]}]},{"name":"Swiss National Science Foundation","award":["108 258"],"award-info":[{"award-number":["108 258"]}]},{"name":"Swiss National Science Foundation","award":["122 504"],"award-info":[{"award-number":["122 504"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life Sciences"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.lfs.2012.07.034","type":"journal-article","created":{"date-parts":[[2012,8,6]],"date-time":"2012-08-06T13:49:42Z","timestamp":1344260982000},"page":"528-539","source":"Crossref","is-referenced-by-count":72,"title":["Clinical trials with endothelin receptor antagonists: What went wrong and where can we improve?"],"prefix":"10.1016","volume":"91","author":[{"given":"Donald E.","family":"Kohan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John G.","family":"Cleland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lewis J.","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Theodorescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Barton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0005","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.toxicon.2011.03.002","article-title":"Bosentan, a selective and more potent antagonist for Atractaspis envenomation than the specific antivenom","volume":"57","author":"Abd-Elsalam","year":"2011","journal-title":"Toxicon"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1172\/JCI200421064","article-title":"Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention","volume":"114","author":"Ahn","year":"2004","journal-title":"J Clin Invest"},{"issue":"9431","key":"10.1016\/j.lfs.2012.07.034_bb0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0140-6736(04)16723-8","article-title":"Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Anand","year":"2004","journal-title":"Lancet"},{"issue":"13\u201314","key":"10.1016\/j.lfs.2012.07.034_bb0020","first-page":"732","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"Andress","year":"2012","journal-title":"Life Sci"},{"issue":"6303","key":"10.1016\/j.lfs.2012.07.034_bb0025","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/348730a0","article-title":"Cloning and expression of a cDNA encoding an endothelin receptor","volume":"348","author":"Arai","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-5793(92)80390-3","article-title":"Conformational study of cyclo[D-Trp-D-Asp-Pro-D-Val-Leu], an endothelin-A receptor-selective antagonist","volume":"296","author":"Atkinson","year":"1992","journal-title":"FEBS Lett"},{"key":"10.1016\/j.lfs.2012.07.034_bb0035","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1016\/j.biocel.2008.01.022","article-title":"The endothelin axis in cancer","volume":"50","author":"Bagnato","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0040","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1161\/HYPERTENSIONAHA.110.156976","article-title":"Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial","volume":"56","author":"Bakris","year":"2010","journal-title":"Hypertension"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0045","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1164\/rccm.200307-957OC","article-title":"Sitaxsentan therapy for pulmonary arterial hypertension","volume":"169","author":"Barst","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.lfs.2012.07.034_bb0050","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.jacc.2006.01.057","article-title":"Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan","volume":"47","author":"Barst","year":"2006","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"10.1016\/j.lfs.2012.07.034_bb0055","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneph0891","article-title":"Reversal of proteinuric renal disease and the emerging role of endothelin","volume":"4","author":"Barton","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"issue":"12","key":"10.1016\/j.lfs.2012.07.034_bb0060","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbadis.2010.03.012","article-title":"Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans","volume":"1802","author":"Barton","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.lfs.2012.07.034_bb0065","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000328859","article-title":"Endothelin antagonists in clinical trials: lessons learned","volume":"172","author":"Barton","year":"2011","journal-title":"Contrib Nephrol"},{"issue":"8","key":"10.1016\/j.lfs.2012.07.034_bb0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1139\/Y08-059","article-title":"Endothelin: 20 years from discovery to therapy","volume":"86","author":"Barton","year":"2008","journal-title":"Can J Physiol Pharmacol"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0075","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1161\/01.HYP.0000245138.09687.8a","article-title":"Role of endothelin receptors for renal protection and survival in hypertension: waiting for clinical trials","volume":"48","author":"Barton","year":"2006","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0080","first-page":"653","article-title":"Profile of past and current clinical trials involving endothelin receptor antagonists: the novel \u201c-sentan\u201d class of drug","volume":"231","author":"Battistini","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0085","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/00005344-199212000-00014","article-title":"Pharmacologic characterization of an endothelinA (ETA) receptor antagonist in conscious rats","volume":"20","author":"Bazil","year":"1992","journal-title":"J Cardiovasc Pharmacol"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0090","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1177\/039463201102400134","article-title":"Evaluation of the effect of bosentan treatment on proinflammatory cytokine serum levels in patients affected by systemic sclerosis","volume":"24","author":"Bellisai","year":"2011","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0095","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1046\/j.1523-1755.1998.00011.x","article-title":"Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy","volume":"54","author":"Benigni","year":"1998","journal-title":"Kidney Int"},{"issue":"11","key":"10.1016\/j.lfs.2012.07.034_bb0100","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/13543784.13.11.1419","article-title":"The potential of endothelin antagonism as a therapeutic approach","volume":"13","author":"Benigni","year":"2004","journal-title":"Expert Opin Investig Drugs"},{"issue":"18","key":"10.1016\/j.lfs.2012.07.034_bb0105","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.ehj.2004.06.038","article-title":"Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure. The Rotterdam Study","volume":"25","author":"Bleumink","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lfs.2012.07.034_bb1000","doi-asserted-by":"crossref","DOI":"10.1021\/jm3009103","article-title":"The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist","author":"Bolli","year":"2012","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/0014-5793(93)81713-A","article-title":"In vitro characterization of Ro 46-2005, a novel synthetic non-peptide endothelin antagonist of ETA and ETB receptors","volume":"334","author":"Breu","year":"1993","journal-title":"FEBS Lett"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0115","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/nm1699","article-title":"Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy","volume":"14","author":"Buckanovich","year":"2008","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0120","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/ndt\/gfr704","article-title":"Endothelin receptor antagonists: a place in the management of essential hypertension?","volume":"27","author":"Burnier","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0125","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s002400000134","article-title":"Apoptotic germ-cell death and testicular damage in experimental diabetes: prevention by endothelin antagonism","volume":"28","author":"Cai","year":"2000","journal-title":"Urol Res"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0130","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.eururo.2005.12.058","article-title":"Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?","volume":"49","author":"Cella","year":"2006","journal-title":"Eur Urol"},{"issue":"9288","key":"10.1016\/j.lfs.2012.07.034_bb0135","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0140-6736(01)06250-X","article-title":"Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study","volume":"358","author":"Channick","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0140","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ncpcardio0540","article-title":"Chronic aspirin therapy for the prevention of cardiovascular events: a waste of time, or worse?","volume":"3","author":"Cleland","year":"2006","journal-title":"Nat Clin Pract Cardiovasc Med"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0145","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/S0735-1097(03)00948-3","article-title":"Delivering the cumulative benefits of triple therapy to improve outcomes in heart failure: too many cooks will spoil the broth","volume":"42","author":"Cleland","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/hrt.66.4.264","article-title":"Vascular tone in heart failure: the neuroendocrine-therapeutic interface","volume":"66","author":"Cleland","year":"1991","journal-title":"Br Heart J"},{"issue":"8","key":"10.1016\/j.lfs.2012.07.034_bb0155","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/euhj.2000.2493","article-title":"The heart failure epidemic: exactly how big is it?","volume":"22","author":"Cleland","year":"2001","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0160","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/S0195-668X(02)00823-0","article-title":"The EuroHeart Failure survey programme \u2014 a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis","volume":"24","author":"Cleland","year":"2003","journal-title":"Eur Heart J"},{"issue":"6\u20137","key":"10.1016\/j.lfs.2012.07.034_bb0165","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.ejheart.2007.01.013","article-title":"Prevalence of markers of heart failure in patients with atrial fibrillation and the effects of ximelagatran compared to warfarin on the incidence of morbid and fatal events: a report from the SPORTIF III and V trials","volume":"9","author":"Cleland","year":"2007","journal-title":"Eur J Heart Fail"},{"issue":"20","key":"10.1016\/j.lfs.2012.07.034_bb0170","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1016\/j.jacc.2009.06.041","volume":"54","author":"Cleland","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"Suppl. 8(2)","key":"10.1016\/j.lfs.2012.07.034_bb0175","first-page":"1126","article-title":"Outcome of patients discharged on loop diuretic therapy with or without a diagnosis of heart failure","author":"Cleland","year":"2009","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.lfs.2012.07.034_bb0180","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/hrt.2010.209171","article-title":"The national heart failure audit for England and Wales 2008\u20132009","volume":"97","author":"Cleland","year":"2011","journal-title":"Heart"},{"issue":"67","key":"10.1016\/j.lfs.2012.07.034_bb0185","doi-asserted-by":"crossref","first-page":"67cm2","DOI":"10.1126\/scitranslmed.3001890","article-title":"Between confidentiality and scientific exchange: the place of publication in drug discovery and pharmaceutical research","volume":"3","author":"Clozel","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6448","key":"10.1016\/j.lfs.2012.07.034_bb0190","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/365759a0","article-title":"Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist","volume":"365","author":"Clozel","year":"1993","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0195","first-page":"228","article-title":"Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist","volume":"270","author":"Clozel","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0200","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.CIR.85.2.504","article-title":"Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure","volume":"85","author":"Cody","year":"1992","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0205","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1388-9842(01)00210-0","article-title":"Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology. WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME","volume":"3","author":"Coletta","year":"2001","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0210","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1388-9842(02)00040-5","article-title":"Clinical trials update: highlights of the scientific sessions of the American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL","volume":"4","author":"Coletta","year":"2002","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0215","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrd3461","article-title":"Mining for therapeutic gold","volume":"10","author":"Collins","year":"2011","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0220","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1097\/00004872-198900076-00044","article-title":"Endothelin has potent direct inotropic and chronotropic effects in cultured heart cells","volume":"7","author":"Concas","year":"1989","journal-title":"J Hypertens Suppl"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0225","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.ejheart.2004.05.004","article-title":"The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A\/B receptor antagonist) in patients with acute heart failure","volume":"6","author":"Cotter","year":"2004","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0230","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S0008-6363(98)00084-4","article-title":"Endothelin-1 has haemodynamic effects at pathophysiological concentrations in patients with left ventricular dysfunction","volume":"39","author":"Cowburn","year":"1998","journal-title":"Cardiovasc Res"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0235","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S0735-1097(98)00663-9","article-title":"Endothelin B receptors are functionally important in mediating vasoconstriction in the systemic circulation in patients with left ventricular systolic dysfunction","volume":"33","author":"Cowburn","year":"1999","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejheart.2004.08.001","article-title":"Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure","volume":"7","author":"Cowburn","year":"2005","journal-title":"Eur J Heart Fail"},{"issue":"18","key":"10.1016\/j.lfs.2012.07.034_bb0245","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1093\/eurheartj\/ehq245","article-title":"Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure","volume":"31","author":"Damy","year":"2010","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0250","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cardfail.2011.12.003","article-title":"Prevalence of, associations with, and prognostic value of tricuspid annular plane systolic excursion (TAPSE) among outpatients referred for the evaluation of heart failure","volume":"18","author":"Damy","year":"2012","journal-title":"J Card Fail"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0255","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/eurheartj\/ehi696","article-title":"Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis","volume":"27","author":"de Silva","year":"2006","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0260","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.amjcard.2006.01.107","article-title":"Anemia, renal dysfunction, and their interaction in patients with chronic heart failure","volume":"98","author":"de Silva","year":"2006","journal-title":"Am J Cardiol"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0265","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1681\/ASN.2005121256","article-title":"The endothelin system and its antagonism in chronic kidney disease","volume":"17","author":"Dhaun","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.lfs.2012.07.034_bb0270","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1159\/000328704","article-title":"Endothelin antagonism in patients with nondiabetic chronic kidney disease","volume":"172","author":"Dhaun","year":"2011","journal-title":"Contrib Nephrol"},{"issue":"14","key":"10.1016\/j.lfs.2012.07.034_bb0275","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2165\/10489160-000000000-00000","article-title":"Bosentan: a review of its use in the management of digital ulcers associated with systemic sclerosis","volume":"69","author":"Dhillon","year":"2009","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0280","first-page":"77","article-title":"Hepatotoxicity by bosentan in a patient with portopulmonary hypertension: a case-report and review of the literature","volume":"20","author":"Eriksson","year":"2011","journal-title":"J Gastrointestin Liver Dis"},{"issue":"15","key":"10.1016\/j.lfs.2012.07.034_bb0285","doi-asserted-by":"crossref","first-page":"PL107","DOI":"10.1016\/0024-3205(92)90353-Q","article-title":"Analysis of responses to endothelins in isolated porcine blood vessels by using a novel endothelin antagonist, BQ-153","volume":"50","author":"Fukuroda","year":"1992","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0290","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1378\/chest.11-0404","article-title":"Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension","volume":"141","author":"Gabler","year":"2012","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0295","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes","volume":"297","author":"Gagliardini","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0300","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jacc.2005.04.050","article-title":"Ambrisentan therapy for pulmonary arterial hypertension","volume":"46","author":"Galie","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0305","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1161\/CIRCULATIONAHA.106.630715","article-title":"Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study","volume":"114","author":"Galie","year":"2006","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.lfs.2012.07.034_bb0310","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1161\/CIRCULATIONAHA.107.742510","article-title":"Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2","volume":"117","author":"Galie","year":"2008","journal-title":"Circulation"},{"issue":"9630","key":"10.1016\/j.lfs.2012.07.034_bb0315","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/S0140-6736(08)60919-8","article-title":"Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial","volume":"371","author":"Galie","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0320","first-page":"386","article-title":"For the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Liver toxicity of sitaxentan in pulmonary arterial hypertension","volume":"32","author":"Galie","year":"2011","journal-title":"Eur Heart J"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0325","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1172\/JCI8609","article-title":"Salt-sensitive hypertension in endothelin-B receptor-deficient rats","volume":"105","author":"Gariepy","year":"2000","journal-title":"J Clin Invest"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0330","doi-asserted-by":"crossref","first-page":"F912","DOI":"10.1152\/ajprenal.00432.2004","article-title":"Collecting duct-specific knockout of endothelin-1 alters vasopressin regulation of urine osmolality","volume":"288","author":"Ge","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"issue":"24","key":"10.1016\/j.lfs.2012.07.034_bb0335","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1056\/NEJM199306173282402","article-title":"Expression of endothelin-1 in the lungs of patients with pulmonary hypertension","volume":"328","author":"Giaid","year":"1993","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.lfs.2012.07.034_bb0340","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1161\/01.CIR.101.25.2922","article-title":"Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure","volume":"101","author":"Givertz","year":"2000","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.lfs.2012.07.034_bb0345","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1097\/01.ASN.0000141313.84470.4B","article-title":"Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism","volume":"15","author":"Goddard","year":"2004","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"10.1016\/j.lfs.2012.07.034_bb0350","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/oxfordjournals.eurheartj.a060446","article-title":"Elevated plasma endothelin concentrations in heart failure; an effect of angiotensin II?","volume":"15","author":"Good","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.lfs.2012.07.034_bb0355","unstructured":"Grass W. Sicherheit und Vertr\u00e4glichkeit, Pharmakokinetik, und Pharmacodynamic des selectiven Endothelin A Rezeptor-Antagonistsn SPP301 bei oraler Mehrfachadministration an gesunde, m\u00e4nnliche Probanden [thesis]. 2006, Institut f\u00fcr Klinische Pharmakologie, Basel, Switzerland, University of Bonn, Germany. 1\u201386. 2006."},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0360","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","article-title":"Immunity, inflammation, and cancer","volume":"140","author":"Grivennikov","year":"2010","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0365","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/bjc.2011.515","article-title":"Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma","volume":"106","author":"Groenewegen","year":"2012","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0370","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/CAD.0b013e328320791c","article-title":"Preclinical anticancer activity of the specific endothelin A receptor antagonist ZD4054","volume":"20","author":"Growcott","year":"2009","journal-title":"Anticancer Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0375","first-page":"14","article-title":"IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton's lymphoma ascites tumor model","volume":"62","author":"Gulati","year":"2011","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0380","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/eurjhf\/hfq002","article-title":"Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure","volume":"12","author":"Harjola","year":"2011","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.lfs.2012.07.034_bb0385","doi-asserted-by":"crossref","first-page":"875","DOI":"10.2165\/11539110-000000000-00000","article-title":"Effects of rifampicin (rifampin) on the pharmacokinetics and safety of ambrisentan in healthy subjects: a single-sequence, open-label study","volume":"30","author":"Harrison","year":"2010","journal-title":"Clin Drug Investig"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0390","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1042\/cs0840427","article-title":"Endothelium-dependent modulation of responses to endothelin-I in human veins","volume":"84","author":"Haynes","year":"1993","journal-title":"Clin Sci (Lond)"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0395","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1183\/09031936.00094409","article-title":"Liver toxicity: the Achilles' heel of endothelin receptor antagonist therapy?","volume":"34","author":"Hoeper","year":"2009","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0400","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1183\/09031936.00193308","article-title":"Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy","volume":"33","author":"Hoeper","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.lfs.2012.07.034_bb0405","unstructured":"Honing MLH, Bouter PK, Ballard DE, Padley P, Morrison PJ, Rabelink TJ. ABT-627, a selective ETA-receptor anatagonist, reduces proteinuria in patients with diabetes mellitus. In: Regulation of Vascular Tone in Humans by Endothelium-derived Mediators [thesis] 2000;Utrecht, The Netherlands: Elinkwijk BV:89\u2013102."},{"issue":"80","key":"10.1016\/j.lfs.2012.07.034_bb0410","doi-asserted-by":"crossref","first-page":"80ps16","DOI":"10.1126\/scitranslmed.3001862","article-title":"The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics","volume":"3","author":"Huang","year":"2011","journal-title":"Sci Transl Med"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0415","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0735-1097(98)00437-9","article-title":"Value of cardiopulmonary exercise testing and big endothelin plasma levels to predict short-term prognosis of patients with chronic heart failure","volume":"32","author":"Hulsmann","year":"1998","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0420","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0425","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/0006-291X(91)91789-F","article-title":"An endothelin receptor (ETA) antagonist isolated from Streptomyces misakiensis","volume":"178","author":"Ihara","year":"1991","journal-title":"Biochem Biophys Res Commun"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0430","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/0024-3205(92)90331-I","article-title":"Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor","volume":"50","author":"Ihara","year":"1992","journal-title":"Life Sci"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0435","doi-asserted-by":"crossref","first-page":"L1040","DOI":"10.1152\/ajplung.2001.280.5.L1040","article-title":"Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction","volume":"280","author":"Ivy","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"25","key":"10.1016\/j.lfs.2012.07.034_bb0440","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1016\/j.jacc.2008.08.059","article-title":"Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial","volume":"52","author":"Jais","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0445","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1358\/dot.2006.42.5.973590","article-title":"Atrasentan: a rationally designed targeted therapy for cancer","volume":"42","author":"Jimeno","year":"2006","journal-title":"Drugs Today (Barc)"},{"key":"10.1016\/j.lfs.2012.07.034_bb0450","doi-asserted-by":"crossref","DOI":"10.1007\/s13277-012-0371-x","article-title":"Circulating levels of endothelin-1 (ET-1) and its precursor (Big ET-1) in breast cancer early diagnosis","author":"Kalles","year":"2012","journal-title":"Tumour Biol"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0455","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/S0735-1097(02)02708-0","article-title":"RITZ-5: randomized intravenous TeZosentan (an endothelin-A\/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study","volume":"41","author":"Kaluski","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"14","key":"10.1016\/j.lfs.2012.07.034_bb0460","doi-asserted-by":"crossref","first-page":"4521","DOI":"10.1158\/1078-0432.CCR-08-0543","article-title":"Endothelin B receptor, a new target in cancer immune therapy","volume":"15","author":"Kandalaft","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0465","first-page":"696","article-title":"Clinical trials of endothelin antagonists in heart failure: a question of dose?","volume":"231","author":"Kelland","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0470","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1136\/hrt.2006.089250","article-title":"Clinical trials of endothelin antagonists in heart failure: publication is good for the public health","volume":"93","author":"Kelland","year":"2007","journal-title":"Heart"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0475","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1593\/neo.10806","article-title":"Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer","volume":"13","author":"Kim","year":"2011","journal-title":"Neoplasia"},{"issue":"8977","key":"10.1016\/j.lfs.2012.07.034_bb0480","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/S0140-6736(95)91504-4","article-title":"Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure","volume":"346","author":"Kiowski","year":"1995","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0485","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/HYPERTENSIONAHA.109.138701","article-title":"Low blood pressure in endothelial cell-specific endothelin 1 knockout mice","volume":"56","author":"Kisanuki","year":"2010","journal-title":"Hypertension"},{"issue":"4876","key":"10.1016\/j.lfs.2012.07.034_bb0490","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1126\/science.2845579","article-title":"Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart and brain","volume":"242","author":"Kloog","year":"1988","journal-title":"Science"},{"key":"10.1016\/j.lfs.2012.07.034_bb0495","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/MNH.0b013e328335f91f","article-title":"Endothelin, hypertension and chronic kidney disease: new insights","volume":"19","author":"Kohan","year":"2010","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0500","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin\u2013angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0505","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1152\/physrev.00060.2009","article-title":"Regulation of blood pressure and salt homeostasis by endothelin","volume":"91","author":"Kohan","year":"2011","journal-title":"Physiol Rev"},{"key":"10.1016\/j.lfs.2012.07.034_bb0510","series-title":"Proceedings of the British Pharmacological Society\/pA2 online","article-title":"Identification of the site of endothelin A receptor antagonist-induced fluid retention (abstract)","author":"Kohan","year":"2011"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0515","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-5793(88)80489-7","article-title":"Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells","volume":"238","author":"Komuro","year":"1988","journal-title":"FEBS Lett"},{"issue":"12","key":"10.1016\/j.lfs.2012.07.034_bb0520","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0525","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1124\/jpet.103.055855","article-title":"Novel dual action AT1 and ETA receptor antagonists reduce blood pressure in experimental hypertension","volume":"309","author":"Kowala","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.lfs.2012.07.034_bb0530","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension","volume":"338","author":"Krum","year":"1998","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0535","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/rheumatology\/keq077","article-title":"Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial","volume":"49","author":"Kuhn","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"10.1016\/j.lfs.2012.07.034_bb0540","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1038\/hr.2009.135","article-title":"Next generation multifunctional angiotensin receptor blockers","volume":"32","author":"Kurtz","year":"2009","journal-title":"Hypertens Res"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0545","first-page":"1307","article-title":"Clinical significance of selected endothelial activation markers in patients with systemic lupus erythematosus","volume":"35","author":"Kuryliszyn-Moskal","year":"2008","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.lfs.2012.07.034_bb0550","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1080\/07357900701522588","article-title":"Endothelin receptor antagonists in cancer therapy","volume":"25","author":"Lalich","year":"2007","journal-title":"Cancer Invest"},{"issue":"8 Pt. 1","key":"10.1016\/j.lfs.2012.07.034_bb0555","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0895-7061(98)00088-0","article-title":"Effects of losartan and captopril on endothelin-1 production in blood vessels and glomeruli of rats with reduced renal mass","volume":"11","author":"Lariviere","year":"1998","journal-title":"Am J Hypertens"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0560","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/j.1600-6143.2005.00807.x","article-title":"Activation of pro-inflammatory and anti-inflammatory cytokines in host organs during chronic allograft rejection: role of endothelin receptor signaling","volume":"5","author":"Lattmann","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.lfs.2012.07.034_bb0565","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1159\/000328988","article-title":"Endothelin antagonism in patients with resistant hypertension and hypertension nephropathy","volume":"172","author":"Lazich","year":"2011","journal-title":"Contrib Nephrol"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0570","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1054\/S1071-9164(03)00125-8","article-title":"Meta-analysis of the effects of endothelin receptor blockade on survival in experimental heart failure","volume":"9","author":"Lee","year":"2003","journal-title":"J Card Fail"},{"issue":"32","key":"10.1016\/j.lfs.2012.07.034_bb0575","doi-asserted-by":"crossref","first-page":"13086","DOI":"10.1073\/pnas.0610292104","article-title":"A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery","volume":"104","author":"Lee","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"24","key":"10.1016\/j.lfs.2012.07.034_bb0580","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0585","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1388-9842(01)00149-0","article-title":"Clinical trials update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the scientific sessions of the American College of Cardiology, 2001","volume":"3","author":"Louis","year":"2001","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.lfs.2012.07.034_bb0590","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1161\/01.CIR.0000038497.80095.E1","article-title":"Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT)","volume":"106","author":"Luscher","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0595","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1681\/ASN.2009060593","article-title":"Avosentan for overt diabetic nephropathy","volume":"21","author":"Mann","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0600","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1378\/chest.08-1028","article-title":"Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities","volume":"135","author":"McGoon","year":"2009","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0605","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1183\/09031936.05.00054804","article-title":"Survival with first-line bosentan in patients with primary pulmonary hypertension","volume":"25","author":"McLaughlin","year":"2005","journal-title":"Eur Respir J"},{"issue":"17","key":"10.1016\/j.lfs.2012.07.034_bb0610","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.lfs.2012.07.034_bb0615","author":"MedPageToday.com"},{"issue":"3 Pt. 2","key":"10.1016\/j.lfs.2012.07.034_bb0620","first-page":"H1070","article-title":"Increased renal endothelin formation is associated with sodium retention and increased free water clearance","volume":"275","author":"Modesti","year":"1998","journal-title":"Am J Physiol"},{"key":"10.1016\/j.lfs.2012.07.034_bb0625","doi-asserted-by":"crossref","first-page":"751513","DOI":"10.4061\/2011\/751513","article-title":"TRC120038, a novel dual AT(1)\/ET(A) receptor blocker for control of hypertension, diabetic nephropathy, and cardiomyopathy in ob-ZSF1 rats","volume":"2011","author":"Mohanan","year":"2011","journal-title":"Int J Hypertens"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0630","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0006-291X(89)92397-8","article-title":"Endothelin is a positive inotropic agent in human and rat heart in vitro","volume":"159","author":"Moravec","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0635","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1161\/01.CIR.96.6.1976","article-title":"Role of endogenous endothelin in chronic heart failure: effect of long-term treatment with an endothelin antagonist on survival, hemodynamics, and cardiac remodeling","volume":"96","author":"Mulder","year":"1997","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0640","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0008-6363(98)00159-X","article-title":"Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure","volume":"39","author":"Mulder","year":"1998","journal-title":"Cardiovasc Res"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0645","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.102.5.491","article-title":"Selective endothelin-A versus combined endothelin-A\/endothelin-B receptor blockade in rat chronic heart failure","volume":"102","author":"Mulder","year":"2000","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0650","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1080\/08916930903002487","article-title":"Mechanisms of vascular damage in systemic sclerosis","volume":"42","author":"Muller-Ladner","year":"2009","journal-title":"Autoimmunity"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0655","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1021\/jm049548x","article-title":"Dual angiotensin II and endothelin A receptor antagonists: synthesis of 2\u2032-substituted N-3-isoxazolyl biphenylsulfonamides with improved potency and pharmacokinetics","volume":"48","author":"Murugesan","year":"2005","journal-title":"J Med Chem"},{"issue":"7 Pt 1","key":"10.1016\/j.lfs.2012.07.034_bb0660","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S0895-7061(02)02933-3","article-title":"Darusentan: an effective endothelin A receptor antagonist for treatment of hypertension","volume":"15","author":"Nakov","year":"2002","journal-title":"Am J Hypertens"},{"issue":"13\u201314","key":"10.1016\/j.lfs.2012.07.034_bb0665","first-page":"586","article-title":"Pharmacokinetic and pharmacodynamic properties of SOL1: a novel dual inhibitor of neutral endopeptidase and endothelin converting enzyme","volume":"91","author":"Nelissen","year":"2012","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0670","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc990","article-title":"The endothelin axis: emerging role in cancer","volume":"3","author":"Nelson","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.lfs.2012.07.034_bb0675","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1002\/cncr.23864","article-title":"Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer","volume":"113","author":"Nelson","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.lfs.2012.07.034_bb0680","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.27674","article-title":"Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone","author":"Nelson","year":"2012","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0685","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2174\/157489006778776990","article-title":"Recent developments on endothelin antagonists as immunomodulatory drugs\u2014from infection to transplantation medicine","volume":"1","author":"Nett","year":"2006","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2012.07.034_bb0690","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1365-2362.2009.02121.x","article-title":"Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence","volume":"39","author":"Neuhofer","year":"2009","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.lfs.2012.07.034_bb0695","doi-asserted-by":"crossref","DOI":"10.1161\/circ.118.suppl_18.S_886","article-title":"Results of a double blind placebo controlled study to evaluate the efficacy and safety of PS433540 in human subjects with hypertension","volume":"118","author":"Neutel","year":"2008","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.lfs.2012.07.034_bb0700","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/S0735-1097(03)00194-3","article-title":"Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4)","volume":"41","author":"O'Connor","year":"2003","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0705","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1161\/01.CIR.89.4.1573","article-title":"Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction","volume":"89","author":"Omland","year":"1994","journal-title":"Circulation"},{"issue":"13","key":"10.1016\/j.lfs.2012.07.034_bb0710","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1161\/01.CIR.0000034444.31846.F4","article-title":"Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan","volume":"106","author":"Ooi","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0715","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/ki.1993.53","article-title":"Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression","volume":"43","author":"Orisio","year":"1993","journal-title":"Kidney Int"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0720","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/0735-1097(95)00520-X","article-title":"Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure","volume":"27","author":"Pacher","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0725","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.cardfail.2004.05.006","article-title":"Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study","volume":"11","author":"Packer","year":"2005","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0730","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1136\/hrt.2004.049734","article-title":"Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study","volume":"92","author":"Prasad","year":"2006","journal-title":"Heart"},{"issue":"Suppl. 2","key":"10.1016\/j.lfs.2012.07.034_bb0735","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2362.2009.02116.x","article-title":"Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension","volume":"39","author":"Pulido","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0740","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0745","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/HYPERTENSIONAHA.108.113068","article-title":"Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis","volume":"52","author":"Raichlin","year":"2008","journal-title":"Hypertension"},{"issue":"9","key":"10.1016\/j.lfs.2012.07.034_bb0750","first-page":"1066","article-title":"Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis","volume":"11","author":"Raja","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0755","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/hrt.2007.134973","article-title":"Quantifying the paradoxical effect of higher systolic blood pressure on mortality in chronic heart failure","volume":"95","author":"Raphael","year":"2009","journal-title":"Heart"},{"issue":"10","key":"10.1016\/j.lfs.2012.07.034_bb0760","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCULATIONAHA.110.967406","article-title":"Long-term administration of endothelin receptor antagonist improves coronary endothelial function in patients with early atherosclerosis","volume":"122","author":"Reriani","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.lfs.2012.07.034_bb0765","author":"Reuters.com"},{"issue":"8","key":"10.1016\/j.lfs.2012.07.034_bb0770","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0025-6196(12)60795-2","article-title":"Increased plasma concentrations of endothelin in congestive heart failure in humans","volume":"67","author":"Rodeheffer","year":"1992","journal-title":"Mayo Clin Proc"},{"issue":"24","key":"10.1016\/j.lfs.2012.07.034_bb0775","doi-asserted-by":"crossref","first-page":"11649","DOI":"10.1158\/0008-5472.CAN-05-2123","article-title":"Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells","volume":"65","author":"Rosano","year":"2005","journal-title":"Cancer Res"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0780","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-07-0151","article-title":"ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo","volume":"6","author":"Rosano","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.lfs.2012.07.034_bb0785","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1073\/pnas.0807158106","article-title":"Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis","volume":"106","author":"Rosano","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"10.1016\/j.lfs.2012.07.034_bb0790","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa012212","article-title":"Bosentan therapy for pulmonary arterial hypertension","volume":"346","author":"Rubin","year":"2002","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0795","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1517\/14728210903571667","article-title":"Anti-endothelin drugs in solid tumors","volume":"15","author":"Russo","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0800","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1172\/JCI42912","article-title":"Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer","volume":"121","author":"Said","year":"2011","journal-title":"J Clin Invest"},{"issue":"6607","key":"10.1016\/j.lfs.2012.07.034_bb0805","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/384353a0","article-title":"Inhibition of myocardial endothelin pathway improves long-term survival in heart failure","volume":"384","author":"Sakai","year":"1996","journal-title":"Nature"},{"issue":"6303","key":"10.1016\/j.lfs.2012.07.034_bb0810","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/348732a0","article-title":"Cloning of a cDNA encoding a non-isopeptide-selective subtype of the endothelin receptor","volume":"348","author":"Sakurai","year":"1990","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0815","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1681\/ASN.2006030208","article-title":"Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism","volume":"18","author":"Sasser","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0820","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1067\/mhj.2001.116760","article-title":"The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure","volume":"142","author":"Schalcher","year":"2001","journal-title":"Am Heart J"},{"key":"10.1016\/j.lfs.2012.07.034_bb0825","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1146\/annurev.pharmtox.47.120505.105134","article-title":"Contrasting actions of endothelin ET(A) and ET(B) receptors in cardiovascular disease","volume":"47","author":"Schneider","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"13\u201314","key":"10.1016\/j.lfs.2012.07.034_bb0830","first-page":"736","article-title":"The dual endothelin converting enzyme\/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans","volume":"91","author":"Seed","year":"2012","journal-title":"Life Sci"},{"key":"10.1016\/j.lfs.2012.07.034_bb0835","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2012.03.032","article-title":"Renal, retinal and cardiac changes in type 2 diabetes are attenuated by macitentan, a dual endothelin receptor antagonist","author":"Sen","year":"2012","journal-title":"Life Sci"},{"issue":"5 Pt. 2","key":"10.1016\/j.lfs.2012.07.034_bb0840","first-page":"H1829","article-title":"Plasma endothelin and renal endothelin are two distinct systems involved in volume homeostasis","volume":"268","author":"Serneri","year":"1995","journal-title":"Am J Physiol"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0845","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1751-7133.2009.00114.x","article-title":"The atrial fibrillation paradox of heart failure","volume":"16","author":"Shelton","year":"2010","journal-title":"Congest Heart Fail"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0850","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1073\/pnas.0307159101","article-title":"Mice with cardiomyocyte-specific disruption of the endothelin-1 gene are resistant to hyperthyroid cardiac hypertrophy","volume":"101","author":"Shohet","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"10.1016\/j.lfs.2012.07.034_bb0855","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1164\/rccm.200404-445OC","article-title":"Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension","volume":"170","author":"Sitbon","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.lfs.2012.07.034_bb0860","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1136\/thx.2005.040618","article-title":"Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first line oral bosentan compared with an historical cohort of patients started on intravenous epoprostenol","volume":"60","author":"Sitbon","year":"2005","journal-title":"Thorax"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0865","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/clpt.2009.15","article-title":"Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects","volume":"85","author":"Smolander","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0870","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.clinthera.2010.01.004","article-title":"Warfarin and bosentan interaction in a patient with pulmonary hypertension secondary to bilateral pulmonary emboli","volume":"32","author":"Spangler","year":"2010","journal-title":"Clin Ther"},{"issue":"16","key":"10.1016\/j.lfs.2012.07.034_bb0875","doi-asserted-by":"crossref","first-page":"7443","DOI":"10.1073\/pnas.88.16.7443","article-title":"Design and synthesis of a specific endothelin 1 antagonist: effects on pulmonary vasoconstriction","volume":"88","author":"Spinella","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0880","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1158\/0008-5472.CAN-08-1879","article-title":"Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade","volume":"69","author":"Spinella","year":"2009","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0885","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2125.2009.03374.x","article-title":"Substrate-specific pharmacokinetic interaction between endothelin receptor antagonists and phosphodiesterase-5 inhibitors\u2013assembling the clues","volume":"67","author":"Srinivas","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.lfs.2012.07.034_bb0890","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ncponc1066","article-title":"Metastasis: a therapeutic target for cancer","volume":"5","author":"Steeg","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0895","doi-asserted-by":"crossref","first-page":"464","DOI":"10.7326\/0003-4819-114-6-464","article-title":"Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?","volume":"114","author":"Stewart","year":"1991","journal-title":"Ann Intern Med"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0900","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s11906-999-0075-9","article-title":"Endothelin in heart failure","volume":"1","author":"Sutsch","year":"1999","journal-title":"Curr Hypertens Rep"},{"issue":"21","key":"10.1016\/j.lfs.2012.07.034_bb0905","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"Sutsch","year":"1998","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.lfs.2012.07.034_bb0910","doi-asserted-by":"crossref","first-page":"7320","DOI":"10.1158\/0008-5472.CAN-05-1403","article-title":"Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2","volume":"65","author":"Titus","year":"2005","journal-title":"Cancer Res"},{"key":"10.1016\/j.lfs.2012.07.034_bb0915","series-title":"Proceedings of the British Pharmacological Society\/pA2 online","article-title":"A phase I, open label, ascending dose study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the endothelin B agonist, SPI-1620, in patients with recurrent or progressive carcinoma (abstract)","author":"Tolcher","year":"2011"},{"issue":"7","key":"10.1016\/j.lfs.2012.07.034_bb0920","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/eurheartj\/ehn096","article-title":"The timing of development and subsequent clinical course of heart failure after a myocardial infarction","volume":"29","author":"Torabi","year":"2008","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.lfs.2012.07.034_bb0925","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacc.2009.05.080","article-title":"Declining in-hospital mortality and increasing heart failure incidence in elderly patients with first myocardial infarction","volume":"55","author":"Torabi","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.lfs.2012.07.034_bb0930","doi-asserted-by":"crossref","DOI":"10.1177\/0091270011423662","article-title":"Clinical pharmacokinetics and drug\u2013drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension","author":"Venitz","year":"2012","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0935","first-page":"857","article-title":"Beneficial cardiovascular effects of endothelin ET(A) receptor blockade in established long-term heart failure after myocardial infarction","volume":"231","author":"Vetter","year":"2006","journal-title":"Exp Biol Med (Maywood)"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0940","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.2009.03384.x","article-title":"The pharmacokinetics and pharmacodynamics of warfarin in combination with ambrisentan in healthy volunteers","volume":"67","author":"Walker","year":"2009","journal-title":"Br J Clin Pharmacol"},{"issue":"Suppl. 5","key":"10.1016\/j.lfs.2012.07.034_bb0945","doi-asserted-by":"crossref","first-page":"S108","DOI":"10.1097\/00005344-198900135-00027","article-title":"Positive inotropic and vasoconstrictive effects of endothelin-1 in in vivo and in vitro experiments: characteristics and the role of L-type calcium channels","volume":"13","author":"Watanabe","year":"1989","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10.1016\/j.lfs.2012.07.034_bb0950","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/HYPERTENSIONAHA.110.160952","article-title":"DORADO: opportunity postponed: lessons from studies of endothelin receptor antagonists in treatment-resistant hypertension","volume":"56","author":"Webb","year":"2010","journal-title":"Hypertension"},{"issue":"9699","key":"10.1016\/j.lfs.2012.07.034_bb0955","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(09)61500-2","article-title":"A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial","volume":"374","author":"Weber","year":"2009","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.lfs.2012.07.034_bb0960","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"22","key":"10.1016\/j.lfs.2012.07.034_bb0965","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1161\/CIRCULATIONAHA.110.938217","article-title":"Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetic hearts through stimulation of endothelial-to-mesenchymal transition","volume":"121","author":"Widyantoro","year":"2010","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.lfs.2012.07.034_bb0970","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/hr.2011.79","article-title":"Epigenetic regulation of pulmonary arterial hypertension","volume":"34","author":"Xu","year":"2011","journal-title":"Hypertens Res"},{"issue":"2","key":"10.1016\/j.lfs.2012.07.034_bb0975","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/01.CIR.0000105701.98663.D4","article-title":"Conditional cardiac overexpression of endothelin-1 induces inflammation and dilated cardiomyopathy in mice","volume":"109","author":"Yang","year":"2004","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.lfs.2012.07.034_bb0980","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1161\/01.CIR.84.6.2280","article-title":"Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects. Evidence for increased production of endothelin in pulmonary circulation","volume":"84","author":"Yoshibayashi","year":"1991","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.lfs.2012.07.034_bb0985","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1161\/CIRCULATIONAHA.105.577288","article-title":"Endogenous endothelin-1 is required for cardiomyocyte survival in vivo","volume":"114","author":"Zhao","year":"2006","journal-title":"Circulation"}],"container-title":["Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320512004122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0024320512004122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,25]],"date-time":"2022-01-25T19:30:14Z","timestamp":1643139014000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0024320512004122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":198,"journal-issue":{"issue":"13-14","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S0024320512004122"],"URL":"https:\/\/doi.org\/10.1016\/j.lfs.2012.07.034","relation":{},"ISSN":["0024-3205"],"issn-type":[{"value":"0024-3205","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}